Project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases

Acronym	NeuroMET2 (Reference Number: 18HLT09)
Duration	01/07/2019 - 30/06/2022
Project Topic	Neurodegenerative diseases (NDDs) are a major health challenge for society; over 9.9 million new cases of dementia are identified worldwide each year, while annual care costs in Europe currently run to €130 billion. More accurate and earlier diagnosis would enable more effective treatment and improve forecasting of disease progression. Improved evaluation of NDD therapies is also needed before clinical uptake can occur. This project aims to develop the most promising, minimally invasive, measurement methods for early NDD diagnosis and will support development of targeted (patient-specific) therapies. The project will lead to improvements in the resolution of magnetic resonance imaging (MRI) and other scanning technologies, validate biomarker measurements and develop a smartphone based cognitive test app – all designed for eventual clinical use. Measurement protocols will support standardisation for early NDD diagnosis and new therapies, enabling development of screening programmes for improved quality of life.
Website	visit project website
Network	EMPIR
Call	EMPIR Call 2018

Project partner

Number	Name	Role	Country
1	LGC Limited	Coordinator	United Kingdom
2	Laboratoire national de métrologie et d'essais	Partner	France
3	Physikalisch-Technische Bundesanstalt	Partner	Germany
4	RISE Research Institutes of Sweden AB	Partner	Sweden
5	Charite - Universitaetsmedizin Berlin	Partner	Germany
6	Centre Hospitalier Universitaire Montpellier	Partner	France
7	Modus Outcomes SAS	Partner	France
8	Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts	Partner	Germany
9	Stichting VUmc	Partner	Netherlands
10	Högskolan Kristianstad	Observer	Sweden